- NEWS AND VIEWS
A bile acid could explain how calorie restriction slows ageing
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-024-04062-1
References
Qu, Q. et al. Nature https://doi.org/10.1038/s41586-024-08329-5 (2024).
Qu, Q. et al. Nature https://doi.org/10.1038/s41586-024-08348-2 (2024).
McCay, C. M., Crowell, M. F. & Maynard, L. A. J. Nutrition 10, 63–79 (1935).
Liao, C.-Y., Rikke, B. A., Johnson, T. E., Diaz, V. & Nelson, J. F. Aging Cell 9, 92–95 (2010).
Mattison, J. A. et al. Nature Commun. 8, 14063 (2017).
Kimura, K. D., Tissenbaum, H. A., Liu, Y. & Ruvkun, G. Science 277, 942–946 (1997).
Lin, S.-J., Defossez, P.-A. & Guarente, L. Science 289, 2126–2128 (2000).
Anderson, R. M., Bitterman, K. J., Wood, J. G., Medvedik, O. & Sinclair, D. A. Nature 423, 181–185 (2003).
Gerisch, B. et al. Proc. Natl Acad. Sci. USA 104, 5014–5019 (2007).
Staats, S. et al. Mol. Nutr. Food Res. 62, e1800424 (2018).
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J. & Schoonjans, K. Nature Rev. Drug Discov. 7, 678–693 (2008).
Bárcena, C. et al. Nature Med. 25, 1234–1242 (2019).
Chen, D. & Guarente, L. Trends Mol. Med. 13, 64–71 (2007).
Martin-Montalvo, A. et al. Nature Commun. 4, 2192 (2013).
Howitz, K. T. et al. Nature 425, 191–196 (2003).
Mercken, E. M. et al. Aging Cell 13, 787–796 (2014).
Krueger, J. G. et al. PLoS ONE 10, e0142081 (2015).
Najt, C. P. et al. Mol. Cell 77, 810–824 (2020).
Song, M. et al. Anim. Nutr. 7, 365–375 (2021).
Kawasumi, H. et al. Oncology 45, 192–196 (1988).
Competing Interests
D.A.S. is a co-founder, consultant, board member and equity owner of Galilei Biosciences and MetroBiotech, companies working to treat diseases with SIRT6 activators and NAD boosters, respectively. He is also an equity owner of Tally Health, a DNA biomarker company. Other activities are listed at sinclair.hms.harvard.edu